Please login to the form below

Not currently logged in
Email:
Password:

Patients prefer AZ asthma drug

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Patients involved in the open-label study favoured Symbicort administered as an adjustable dose treatment option as opposed to Advair. The two drugs have a similar mode of action and are competing against each other in the large and lucrative asthma market.

"These data showed that patients treated with Symbicort combination therapy fixed dose were more satisfied with the timelines of their symptom relief than those patients treated with Advair combination," said Dr Richard O'Connor, lead investigator of the study.

Despite being available as an adjustable dose treatment in over 87 countries, Symbicort is not indicated for that use in the US but was launched as a long-term maintenance treatment last year.

GSK reported global sales of Adviar worth $6.4bn in 2007 where as AZ recorded sales worth $1.6bn during the same year.

21st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics